公开(公告)号：US11746109B2

公开(公告)日：2023-09-05

申请号：US16088096

申请日：2017-03-27

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Kentaro Iwata ,  Masahiro Mizuno ,  Kazuhiro Maeda ,  Tsuneo Yasuma ,  Misaki Homma ,  Yuya Oguro ,  Naohiro Taya ,  Lei Zhu ,  John Daniel Bailey ,  Marianne Langston ,  Siddhesh Dinanath Patil ,  Shruti Gour ,  Lilly Roy

IPC: C07D471/08 ,  A61K9/48

CPC classification number: C07D471/08 ,  A61K9/485 ,  A61K9/4858 ,  C07B2200/13

Abstract: The present disclosure relates to crystalline forms of 2-[(2S)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3H)-one hemihydrate (Compound 1) and/or tautomers thereof, wherein Compound 1 has the structure: (I)·0.5H2O; processes for preparing crystalline forms of Compound 1 and/or tautomers thereof; pharmaceutical compositions comprising the crystalline forms; methods of inhibiting a cell division cycle 7 in a mammal comprising administering the crystalline forms; and methods of treating a cell division cycle 7 mediated cancer in a mammal comprising administering the crystalline forms or a pharmaceutical composition comprising the crystalline forms.